Tirzepatide 30mg

Tirzepatide is a dual-receptor agonist peptide that targets two key metabolic pathways. The GLP-1 receptor (Glucagon-Like Peptide-1) enhances insulin secretion in response to glucose, improves beta cell function, and promotes satiety signaling in the brain. The GIP receptor (Glucose-dependent Insulinotropic Polypeptide) works synergistically to further stimulate insulin release in a glucose-dependent manner while modulating appetite regulation. Together, these dual mechanisms support comprehensive glucose homeostasis and metabolic control.

Tirzepatide 30mg is administered as a weekly subcutaneous injection, providing sustained receptor activation for research applications.